Факторы риска развития кардиоваскулярных заболеваний у больных подагрой
Диссертация
Несмотря на большой прогресс, достигнутый за последние десятилетия в диагностике и лечении кардиоваскулярных заболеваний (КВЗ), эта патология остается ведущей причиной сокращения продолжительности жизни населения нашей планеты. По оценкам Всемирной Организации Здравоохранения (ВОЗ), каждый год в мире от КВЗ погибают более 17 млн. человек, из них более 7 млн. от ишемической болезни сердца (ИБС… Читать ещё >
Содержание
- ГЛАВА 1. ОБЗОР ЛИТЕРАТУРЫ
- ГЛАВА 2. МАТЕРИАЛЫ И МЕТОДЫ ИССЛЕДОВАНИЯ
- 2. 1. Клиническая характеристика обследованных больных
- 2. 2. Клинические методы исследования
- 2. 3. Инструментальные методы исследования
- 2. 4. Лабораторные методы исследования
- 2. 5. Методы статистической обработки
- ГЛАВА 3. СОБСТВЕННЫЕ РЕЗУЛЬТАТЫ
- 3. 1. Риск развития кардиоваскулярной патологии у больных подагрой
- 3. 2. Кардиоваскулярные факторы риска у больных подагрой в зависимости от наличия ИБС
- 3. 3. Связь между концентрацией вч-СРБ, СОЭ и кардиоваскулярной патологией у пациентов с подагрой
- 3. 4. Связь между кардиоваскулярными факторами риска, толщиной комплекса интима-медиа, нарушениями функции эндотелия у больных подагрой
- ОБСУЖДЕНИЕ
- ВЫВОДЫ
Список литературы
- Карпов Ю.А., Сорокин Е. В. Стабильная ишемическая болезнь сердца: стратегия и тактика лечения //Реафарм. Москва, 2003, — С. 7−16.
- Wyngaarden J.B., Kelley W.N. Gout and hyperuricemia // New York, 1976. -P. 32−33.
- Vazquez-Mellado J., Garsia Garsia C., Guzman Vazquez S. et al. Metabolic Syndrome and Ischemic Heart Disease in Gout // J. Clin. Rheumatol. 2004,-Vol.10.- P.105−109.
- Emmerson B.T., Knowles B.R. Trigliceride concentration in primary gout and gout of chronic lead nephropathy// Metabolism. 1971, — Vol. 20, — P.721−729.
- Takahashi S., Moriwaki Y., Tsutsumi Z. et al. Increased visceral fat accomulation further aggravates the risk of insulin resistance in gout // Metabolism.-2001Vol.50. № 4. — P. 393- 398.
- Engelhardt H.T., Wagner E.L. Gout, diabetes mellitus and obesity, a poorly recognized syndrome // South. Med. J.- 1950, — Vol. 43, — P.51−53.
- Mikkelsen W.M. The possible association of hyperuricemia and/or gout with diabetes mellitus // Arthritis Rheum.- 1965, — Vol. 8.- P. 853−864.
- Berkowitz D. Gout, hyperlipidemia and diabetes interrelationships // JAMA-1966.-Vol.197.-P. 77−80.
- Kuzell W.C., Schaffarzick R.W., Naugler W.E. et al. Some observations on 520 gouty patients // J.Chronic. Dis.-1995.- Vol.2.- P. 645−669.
- Barlow K.A., Beilin L.J. Renal disease in primary gout // Q.J.Med.- 1968.-Vol.37.- P.79−96.
- Rapado A. Relationship between gout and arterial hypertension// Adv. Exp. Med. Biol.- 1974.- Vol.41.- P.451−459.
- Weiss Т.Е., Segaloff A. Gouty Arthritis and Gout// Springfield, III, Thomas, 1959.- P.7.
- Grahame R., Scott J.T. Clinical survey of 354 patients with gout// Ann. Rheum. Dis.- 1970, — Vol.29.-P.461−468.
- Fang, J, Alderman, MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971−1992. National Health and Nutrition Examination Survey// JAMA.- 2000, — Vol.283. P.2404.
- Freedman, DS, Williamson, DF, Gunter, EW, Byers, T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study//Am J Epidemiol.- 1995, — Vol.141. P.637.
- Brand, FN, McGee, DL, Kannel, WB, et al. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study// Am J Epidemiol.- 1985. Vol. 121. P.ll.
- Niskanen, LK, Laaksonen, DE, Nyyssonen, K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study// Arch Intern Med.- 2004, — Vol.164 P.1546.
- Ross R. Atherosclerosis an inflammatory disease// N. Engl. J. Med.-1999.-Vol.340. P.115−126.
- Glass C.K., Witztum J.L. Atherosclerosis: the road ahead// Cell.- 2001.-Vol.104. P. 503−516.
- Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization// Am J Cardiol.-2000, — Vol. 86,-Suppl.3J-9J.
- Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis// Circulation.- 2002, — Vol.105. P.1135−1143.
- Libby P. Vascular biology of atherosclerosis: overview and state of the art// Am J Cardiol. 2003.- Vol. 91, — Suppl. 3A-6A.
- Biasucci L.M., Vitelli A., Liuzzo G. Elevated levels of IL-6 in unstable angina// Circulation.- 1996, — Vol.94. P.506−512.
- Bataille R., Klein R. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo// Arthritis Rheum.- 1992, — Vol.35.-P.282−283.
- Rifai N., Tracy R.P., Ridker P.M. Clinical efficacy of an automated highsensitivity C-reactive protein assay// Clin Chem.- 1999, — Vol.45.-P.2136−2141.
- Roberts W.L., Sedrick R., Moulton L. et al. Evaluation of four automated high-sensitive C-reactive protein methods- implications for clinical and epidemiological applications// Clin Chem.- 2000, — Vol.46.-P.461−468.
- Roberts W.L., Moulton L., Law T.C. et al. Evaluation of nine automated high sensitive C-reactive protein methods: implications for clinical and epidemiological applications//Clin Chem.-2000.- Vol.47.- P.418−423.
- Ockene I.S., Mathews C.D., Rifai N. et al. Validity and classification accuracy of serial nigh-sensitive C-reactive protein measurements in healthy adults//Clin Chem.- 2001, — Vol.47.- P.444−450.
- Tracy R.P. Inflammation markers and coronary heart disease// Curr.Opin. Lipidol.- 1999.- Vol.10.-P.435−441.
- Ridker P.M. Evaluating novel cardiovascular risk factor can we better predict heart attack?// Ann Intern Med.- 1999, — Vol. l30.-P.933−937.
- Ridker P.M. High-sensitive C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease// Circulation.- 2001,-Vol.103.- P.1813−1818.
- Rader D.J. Inflammatory markers of coronary risk// N Engl J Med.- 2000.-Vol.343.- P. l 179−1182.
- Koening W. Atherosclerosis involves more than just li pids: focus on inflammation// Eur Heart J.- 1999.- Suppl T.-Tl 9-T26.
- Lagrand W.K., Visser C.A., Hermens W.T.et al. C-reactive protein as cardiovascular risk factor: more than an epiphenomenona.// Circulation.- 1999,-Vol.1000.- P.966 102.
- Насонов E.JI. Маркеры воспаления и атеросклероз: значение С-реактивного белка//Кардиология. 1999, — Vol. 2, — Р.81−85.
- Liuzzo G., Biasucci L.M., Gallimore J.R. et al. The prognostic value of C-reactive protein and serum amiloid A protein in severe unstable angina.// N Engl J Med.- 1994.- Vol.331.-P.417.
- Morrow D.A., Rifai N., Antman E.M. et al. C-reactive protein is a potent predictor of mortality independentally of and in combination with troponin «in acute coronary syndrome: а ТГШ ПА study// J Am Coll Cardiol.- 1988, — Vol.31.- P. 14 601 465.
- Biasucci L., Liuzzo G., Grillo R.L. et al. Elevated Levels of C-reactive protein at discharge in patients with Unstable angina predict recurrent instability// Circulation.- 1999, — Vol.99.- P.855−860.
- Toss H., Lindahl В., Siegbahn A. et al. For the FRISC Study Group. Prognostic influence of fibrinogen and C-reactive protein levels in unstable coronary artery disease.// Circulation.- 1997.-Vol.96.- P.4204−4210.
- Linahl В., Toss H., Siegbahn A. et al. For FRISC Study Group. Markers of myocardial damage and inflammation in relationship to long-term mortality in unstable coronary artery disease.//N Engl J Med. 2000, — Vol.343.- P. l 139−1147.
- Braumvald E. Shattuck lecture cardiovascular medicine at the turn of millennium: triumph, concerns, and opportunities// N. Engl. J Med. -1997.-Vol.337,-P.1360−1369.
- Sattar N., McCarey D.W., Capel H. et al. Explaining how „high grade“ systemic inflamation accelerates vascular risn in rheumatoid arthritis.// Circulation.-2003, — Vol.108.-P. 2957−2963.
- Park Y-B, Aim C-W, Choi HK, et al. Atherosclerosis in rheumatoid arthritis. Morphologic evidence obtained by carotid ultrasound // Arthritis Rheum.- 2002.-Vol. 46, — P. l714−1719.
- Johsson SW, Backman C, Johnson О, Karp K, et al. Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis.// J Rheumatology.-2001, — Vol. 28. P.2597−2602.
- Grundy SM. Inflammation, metabolic syndrome, and diet responsiveness.// Circulation. -2003,-Vol. 108, — P.126 -128.
- Festa A, D’Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)// Circulation. -2000, — Vol.102.- P.42- 47.
- Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women // Circulation.- 2003.- Vol. 107.- P.391−397.
- Grundy SM. Inflammation, hypertension, and the metabolic syndrome // JAMA.- 2003.- Vol.290.- P.3000−3002.
- Насонова В.А., Барскова В. Г. Ранние диагностика и лечение подагры -научно обоснованное требование улучшения трудового и жизненного прогноза больных.// Научно-практич. ревматол, — 2004, — Vol. 1.-Р. 5−7.
- World Health Organ. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. // Tech. Rep. Ser. 2000, — Vol.894.- i-xii.- P.l.
- Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA// 2002.- 16.- 287 (3).- P.356−359.
- Khaodhiar L., McCowen K.C., Blackburn G.L. Obesity and comorbid conditions.// Clin. Cornestone.- 1999.- Vol.2 (3).- P. 17−31.
- Bieber J.D., Terkeltaub R.A. Gout. On the brink of novel therapeutic options for an ancient disease.// Arthr Rheum.- 2004, — Vol. 50, — № 8.- P. 2400−2414.
- Zavaroni I, Mazza S, Fantuzzi M. Changes in insulin and lipid metabolismin males with asymptomatic hyperuricaemia.// J Intern Med.- 1993, — Vol.234(l). P.25−30.
- Despres J-P. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients' risk.// Obes. Res .1998,6,1,8S-17S.
- Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases.// Nutrition.- 1997, — Vol.13.-P.795−803.
- Gutman A.B. Views on the pathgenesis and management of primary gout -1971.// J. Bone Joint Surg.- 1972, — Vol. 54А, — P.357−372.
- Brand F.N., McGee D.L., Kannel W.B. Hyperuricemia as a risk factor of coronary heart disease.// Am. J. Epidemol.-1985.- Vol.121.- P. ll-18.
- Assman G., Cullen P., Schulte H. The Munster heart study (PROCAM).// Europ. Heart J.-1998, — Vol. 19, — Suppl. А, — P. A2-A11.
- Оганов Р.Г. Факторы риска и профилактика сердечно-сосудистых заболеваний.// Болезни сердечно-сосудистой системы, — 2003, — № 2.- С. 10 15.
- Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) //Circulation.- 2002, — Vol.106.- P.3143.
- Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.// Lancet.- 2004- Vol.364.- P.937.
- Vasan R.S., Sullivan L.M., Wilson PW. et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors.// Ann Intern Med.- 2005, — Vol. 142, — P.393.
- Wilson PWF, D’Agostino RB, Levy D. Prediction of coronary heart disease using risk factor categories // Circulation. 1998. — Vol.97. — P.1837−1847.S
- Jousilahti P., Vartiainen E., Tuomilehto J. et al. Sex, age, cardiovascular risk factors, and coronary heart disease: A prospective follow-up study of 14,786 middle-aged men and women in Finland // Circulation. 1999. — Vol. 99, — P. l 165.
- Chobanian A.V., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report // JAMA.- 2003, — Vol.289. P.2560.
- Franklin S.S., Larson M.G., Khan S.A. et al. Does the relation of blood pressure to coronary heart disease risk change with aging?: the Framingham Heart Study //Circulation. 2001. — Vol.103. — P.1245.e
- Lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies // Lancet. 2002. — Vol. 360. — P. 1903.
- Wilking S.V., Belanger A.J., Kannel W.B. et al. Determinants of isolated systolic hypertension // JAMA. 1988. — Vol. 260. — P.3451.1
- Roncaglioni M.C., Santoro L., D’Avanzo B. et al. Role of family history in patients with myocardial infarction: An Italian case-control study. GISSI-EFRIM Investigators // Circulation. 1992. — Vol.85. — P.2065.
- Genest J.J., Martin-Munley S.S., McNamara J.R. et al. Familial lipoprotein disorders in patients with premature coronary artery disease // Circulation.- 1992. -Vol.85. P.2025.
- Song Y., Stampfer M.J., Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease // Ann. Intern. Med. 2004. — Vol.141.- P.137.a
- Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group // N. Engl. J. Med. 1995. — Vol. 333. — P. 1301.
- Downs J.R., Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS//JAMA.- 1998. Vol.279. -P.1615.
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial // Lancet. 2002. -Vol. 360. — P.7.
- Wilhelmsson C., Vedin J.A., Elmfeldt D. et al. Smoking and myocardial infarction // Lancet. 1975. — Vol.1. — P.415.
- Rosenberg L., Kaufman D.W., Helmrich S.P. et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age // N. Engl. J. Med. -1985.-Vol.313.-P.1511.
- Njolstad I., Arnesen E., Lund-Larsen P.G. Smoking, serum lipids, blood pressure and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study//Circulation. 1996. — Vol. 93. -P.450.
- Prescott E., Hippe M., Schnohr P. et al. Smoking and the risk of myocardial infarction in women and men: Longitudinal population study // BMJ. 1998. — Vol. 316.-P.1043.
- Kannel W.B., McGee D.L. Diabetes and cardiovascular risk factors: The Framingham Study// Circulation. 1979. — Vol. 59. -P.8.
- Kannel W.B., McGee D.L. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study // Diabetes Care. 1979. — Vol. 2. -P.120.
- Reaven G.M. Banting Lecture 1988: Role of insulin resistance in human disease//Diabetes. 1988. — Vol. 37. — P. 1595.
- Zavaroni I., Bonora E., Pagliara M. et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance // N Engl J Med. 1989. — Vol. 320. — P.702.
- Singer D.E., Nathan D.M., Anderson K.M. et al. Association of HbAlc with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study// Diabetes. 1992. — Vol. 41. -P.202.
- Gerstein H.C., Pais P., Pogue J. et al. Relationship of glucose and insulin level to the risk of myocardial infarction: A case-control study // J. Am. Coll. Cardiol. -1999.-Vol. 33.-P.612.
- Al-Delaimy W.K., Merchant A.T., Rimm E.B. et al. Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men // Am. J. Med. -2004, — Vol. 116- P.236.
- Cook D.G., Shaper A.G., Thelle D.S., Wliitehead T.P. Serum uric acid, serum glucose and diabetes: relations in a population study // Postgrad. Med. J. 1986. -Vol. 262. -P.1001−1006.
- Whitehead T.P., Jungner I., Robinson D. et al. Serum urate, serum glucose and diabetes // Ann. Clin. Biochem. 1992. — Vol. 29. — P.159−161.
- Norhammar A., Tenerz A., Nilsson G. et al. Glucose metabolism in patients with acute myocardial infarction, and no previous diagnosis of diabetes mellitus: A prospective study // Lancet. 2002. — Vol. 359. — P.2140.
- Qiao Q., Pyorala K., Pyorala M. et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose // Eur. Heart J. 2002. — Vol. 23. — P.1267.
- Eckel R.H., York D.A., Rossner S. et al. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary // Circulation. 2004. — Vol. 110. — P.2968.
- Calle E.E., Thun M.J., Petrelli J.M. et al. Body-mass index and mortality in a prospective cohort of U.S. adults see comments. // New Eng. J. Med. 1999. — Vol. 341.-P.1097.
- Choi H.K., Atkinson K., Karlson E.W. et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men // New Engl. J. Med. 2004. — Vol. 350. -P.1093−103.
- Reaven G.M. Pathophysiology of insulin resistance in human disease // Physiol. Rev. 1995. — Vol. 75. — P.473−486.
- Grundy S.M. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome // Am. J. Cardiol. 1999. — Vol. 83. — P.25F-29 °F.
- Sattar N., Gaw A., Scherbakova O. et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study // Circulation. 2003. — Vol. 108. -P.41419.
- Onat A., Ceyhan K., Basar O. et al. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels: a prospective and cross-sectional evaluation // Atherosclerosis. 2002. — Vol. 165. — P.285−292.
- Lakka H.M., Laaksonen D.E., Lakka T.A. et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men // JAMA.2002. Vol. 288. — P.2709−2716.
- Resnick H.E., Jones K., Ruotolo G. et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study // Diabetes Care. 2003. — Vol. 26. — P.861−867.
- Adams P.F., Hendershort G.E., Marano M.A. Current estimates from the National Health Interview Survey, 1996// Vital. Health. Stat. 1999. — Vol.10. -P.200.
- Arromdee E., Michet C.J., Crowson C.S. et al. Epidemiology of Gout: Is the Incidence Rising // J. Rheumatol. 2002. — Vol. 29. — P.2403−2406.
- Lowrence R.C., Helmick C.G., Arnett F.C. et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States // Arthritis. Rheum. 1998. — Vol. 41. — P.778−799.
- Grundy S.M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome // Am. J. Cardiol. 1998. — Vol. 81. — P.18B-25B.
- Fagan T.C., Deedwania P.C. The cardiovascular dysmetabolic syndrome // Am. J. Med. 1998. — Vol. 105. — P.77S-82S.
- Goldberg R.B., Capuzzi D. Lipid disorders in type 1 and type 2 diabetes // Clin. Lab. Med. -2001. Vol. 21. — P. 147−171.
- Tedde R., Sechi L.A., Marigliano A. et al. Antihypertensive effect of insulin reduction in diabetichypertensive patients // Am.J. Hypertens. 1989. — Vol. 2. — P. 163−170.
- Randeree H.A., Omar M.A.K., Motala A.A., Seedat M.A. Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure // Diabetes Care.- 1992.-Vol. 15.-P.1258−1263.
- Cristlieb A.R., Krolewski A.S., Warram J.H., Soeldner I.S. Is insulin the link between hypertention and obesity? // Hypertention. 1985. — Vol. 7. — P. П54-П57.
- Manicardi V., Camellini L., Bellodi G. et al. Evidence for an association of high blood pressure and hyperinsulinrmia in obese man // J. Clin. Endocrinol. Metab. 1986. — Vol. 62. — P.1302 -1304.
- Rose H.G., Yalow R.S., Schweitzer P., Schwartz E. Insulin as a potential factor influencing blood pressure in amputees // Hypertension. 1986. — Vol. 8. — P.793−800.
- Modan M., Halkin H., Almog S. et al. Hyperinsulinemia: a link between hypertention obesity and glucose intolerance // J. Clin. Invest. 1985. — Vol. 75. — P. 809−817.
- Tappy L., Bovet P., Jequier T. et al. Relationship ofof fasting serum insulin concentrations with blood pressure in a representative sample of the adult population of the Seychelles // Int. J. Obesity. 1991. — Vol. — 15. -P.669 — 675.
- Fournier A.M., Gadia M.T., Kubrusly D.B. et al. Blood pressure, insulin, and glycemia in nondiabetic subjects // Am. J. Med. 1986. — Vol. 80. — P.861 — 864.
- Оганов Р.Г., Александров Ан.А. Инсулин и артериальная гипертония: роль гиперсимпатикотонии // Тер. Архив. 2002. — № 12. — т.74. — С.24−26.
- Andromico G., Mangano М.Т., Nardi Е. et al. Insulin like groth factor-1 and sodium-lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy // J. Hypertens. — 1993. — Vol. 11. — P. 1097−1103.
- Diez J., Laviades C., Martinez E. et al. Insulin like grouth factor binding protein in arterial hypertension relationship to left ventricular hypertrophy // Ibid. -1995,-Vol. 13. -P.49−35.
- Sesso H.D., Lee I.M., Gaziano J.M. et al. Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women // Circulation. 2001. — Vol. 104. — P.393.
- Vasan R.S., Sullivan L.M., Wilson P.W. et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors // Ann Intern Med. 2005. — Vol. 142. — P.393.
- Wilson P.W. Established risk factors and coronary artery disease: The Framingham Study // Am. J. Hypertens. 1994. — Vol. 7. — P.7S.
- Assman G., Cullen P., Schulte H. The Munster heart study (PROCAM) // Europ. Heart J. 1998 — Vol. 19 (Suppl. A) — P. A2 — Al 1
- Conroy R.M., Pyorala K., Fitzgerald A. P et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project // Eur Heart J. 2003. -Vol. 24.-P.987.
- Assmann G., Cullen P., Schulte H. et al. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study // Circulation. 2002. — Vol. 105. -P.310.
- Wallis E.J., Ramsay L.E., U1 Haq I. et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population // BMJ. 2000. — Vol. 320. — P.671.
- D’Agostino R.B., Grundy S., Sullivan L.M. et al. Validation of the Framingham Coronary Heart Disease Prediction Scores: Results of a Multiple Ethnic Groups Investigation // JAMA. 2001. — Vol. 286. — P. 180.
- Ford E.S., Giles W.H., Mokdad A.H. et al .The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III // J Am Coll Cardiol. 2004. — Vol. 43 — P. 1791.
- Tousoulis D., Davies G., Stefanadis C. et al. Inflammatory and thrombotic mechanisms in coronary atherosclerosis // Heart. 2003. — Vol. 89. — P.993−997.
- Altman R. Risk factors in coronary atherosclerosis athero-inflammation: the meeting point // Thrombosis journals. 2003. — Vol. 1. — P.4.
- Stollberger C., Finsterer J. Role of infectious and immune factors in coronary and cerebrovascular arteriosclerosis // Clin Diagn Lab Immunol. 2002. — Vol. 9. -P. 207−215.
- Zebrack J.S., Anderson J.L. The role in inflammation and infection in the pathogenesis and evaluation of coronary artery disease // Curr. Cardiol. Report -2002,-Vol. 4.-P. 278−288.
- Ridker P.M. Evaluating novel cardiovascular risk factor can we better predict heart attack? // Ann. Intern. Med. 1999. — Vol. 130. — P.933−937.
- Blake GJ, Ridker PM. Novel Clinical Markers of vascular wall inflammation Circ Res 2001- 89: 763−771.
- Насонов EJI. Иммунологические маркеры атеросклероза // Терапевт архив. 2002. — № 5. — С.80−85
- Szmitko Р.Е., Wang С.Н., Weisel R.D. et al. New markers of inflammation and endothelial cell activation, part II // Circulation. 2003. — Vol.108. — P.2041−2048.
- Насонов E.JI. Иммунологические маркеры атеросклероза. В кн: Антифосфолипидный синдром / М.: Издательство „Литтера“. 2004. — Р. 278 298.
- Shine В., de Beer F.C., Pepys М.В. Solid phase radioimmunoassays for C-reactive protein //Clin.Chim.Acta. 1981. — Vol. 117. -P.13−23.
- Ballou S.P., Kushner I. C-reactive protein and the acute phase response // Adv. Intern.Med. 1992. — Vol.37. -P.313−336.
- Young В., Gleeson M., Cripps A. C-reactive protein: a critical review // Pathology. 1991. — Vol.23. -P.l 18−124.
- Steel D.M., A.S.Alexander. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid protein A // Immunol.Today. 1994. — Vol.74. -P.80−87.
- Vigushi D.M., Pepys M.D., Hawkins P.N. Metabolic and scintigraphic studies of radiodinated human C-reactive protein in health and disease // J.Clin.Invest. -1993,-Vol.91.-P.1351−1357.
- Bataile R., Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. // Arthritis Rheum. 1992. — Vol.35. — P.982−984.
- Macy E.M., Hayes Т.Е., Tracy R.P. Variability in the measurement of of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological application// Clin.Chem. 1997. — Vol.43. — P.52−58.
- Rifai N., Tracy R.P., Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay// Clin.Chem. 1999. — Vol.45. -P.2136−2141.
- Roberts W.L., Sedrick R., Moulton L. et al. Evaluation of four automatet high-sensitivity C-reactive protein methods: implication for clinical and epidemiological applications // Clin.Chem. 2000. — Vol.46. — P.461−468.
- Rifai N., Ridker P.M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease // Clin.Chem. 2001. — Vol.47. P.403−411.
- Roberts W.L., Moulton L., Law T.C. et al. Evaluation of nine automated high-sensitivity C-reactive protein methods implication for clinical and epidemiological applications Part 2 // Clin.Chem. 2001. — Vol.47. — P.418−425.
- Rothkrantz-Kos S., Schmitz M.P., Bekers O. et al. High-sensitivity C-reactive protein methods examined // Clin.Chem. 2002. — Vol.48. P.359−362.
- Ledue T.B., Weiner D.L., Sipe J.D. et al. Analytical evaluation of particle-enchanced immunonephelometric assays for C-reactive proteins, serum amiloid A and mannose-binding protein in human serum // Ann.Clin.Biochem. 1998. — Vol.35. — P.745−753.
- BorqueL., Bellod L., Rus A. et al. Development and validation of an automated and ultrasensitive immunoturbidimetric assay for C-reactive protein // Clin.Chem. -2000.-Vol.46-P.l 839−1842.
- Rifai N., Tracy R.P., Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay // Clin.Chem. 1999. — Vol.45. — P.2136−2141.
- Rifai N., Ridker P.M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease // Clin.Chem. 2001. — Vol.47. — P.403−411.
- Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention // Circulation. 2003. — Vol.107. — P. Vol.363−369.
- Mendall M.A., Strachman D.P., Butland B.K., et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in man // Eur. Heart J. 2000. — Vol.21. — P. 1584−1590.
- Ridker P., Hennekens C., Buring J.E. et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women // New Engl. J. Med. 2000. — Vol.342 -P.836−843.
- Ridker P., Rifai N., Clearfield M. et al. Measurement of C-reactive protein for the targering of statin therapy in the primary. prevention of acute coronary events // New Engl. J. Med.-2001. Vol.344.-P.1959−1965.
- Danesh J., Whincup P.M., Walker M. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analysis // Br. Med. J. -2000. Vol.321.-P. 199−204.
- Pradhan A.D., Manson J.E., Rossouw J.E. et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study // JAMA.- 2002. -Vol.336.-P. 973−979.
- Ridker P.M., Rifai N., Stampfer M.J. et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men // Circulation. 2000. — Vol.101. — P. 1767−1772.
- Albert M.A., Danielson E., Rifai N. et al. Effects of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study // JAMA. 2001. — Vol.286. P.64−70.
- Kuller L. H, Tracy R.P., Shaten J. et al. for MRFIT research group. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study// Am. J. Epidemiol. 1996. — Vol.144. -P.537−547.
- Biasucci L., Liuzzo G., Grillo R. et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability // Circulation. 1999. -Vol.99. -P.855−860.
- Haverkate F., Thompson S.G., Руке S.D.M. et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina // Lancet. 1997. -Vol.349. -P.462−466.
- Mueller C., Buettner H.J., Hodgson K.M. et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients // Circulation. 2002. — Vol.105 -P.1412−1415.
- Sakkinen P., Abbott R.D., Curd J.D. et al. C-reactive protein and myocardial infarction // J. Clin. Epidemiol. 2002. — Vol.55. — P.445−451.
- Winbeck K., Popper H., Etgen T. et al. Prognostic relevance of early serial C-reactive protein measurement after first ischemic stroke // Stroke. 2002. — Vol.33. -P.2459−2464.
- Ridker P.M., Buring J.E., Cook N.R. et al. C-reactive protein, the methabolic syndrome, and risk of incident cardiovascular events: an 8-years follow-up of 14 719 initially healthy American women // Circulation. 2003. — Vol.107. — P.391−397.
- Ridker P.M., Buring J.E., Cook N.R. et al. C-reactive protein, the metabolic syndrome, anf risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women // Circulation. 2003. — Vol.107. — P.391−397.
- Suwaidi J.A., Hamasaki S., Higano S.T. et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction // Circulation.- 2000. -Vol.101. -P.948.
- Schachinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease // Circulation.- 2000. Vol.101. — P.1899.
- Heitzer Т., Schlinzig Т., Krohn K. et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease // Circulation. 2001. — Vol.104.- P.2673.
- Malik A.B., Lo S.K. Vascular endothelial adhesion molecules and tissue inflammation // Lab. Invest. 1996. — Vol.48. — P.213−229.
- Cinez D.B., Pollak E.S., Buck C.A. et al. Endothelial cells in physiology an in the pathophysiology of vascular disorders // Blood. 1998. — Vol.91. — P.3527−3561.
- Salogin K.V., Nasonov E.L., Belenkov Yu.N. The role of endothelial cell in immunopathology // Sov. Arch. Int. Med. 1992. — Vol.64. — Suppl.l. — P.16−24.
- Muller W.A. Leukocyte-endothelial cell interactions in the inflammatory response // Lab. Invest. 2002. — Vol.82. — P.521−533.
- Tedgui A., Mallat Z. Anti-inflammatory mechanisms in the vascular wall // Circ. Res. 2001. — Vol.88. — P.877−887.
- Celermajer D. S, Sorensen K.E., Gooch V.M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk atherosclerosis // Lancet.- 1992. -Vol.340. P. l 111−1115.
- Corretti M.C., Anderson T.J., Benjamin E.J. et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of brachial artery // Jam. Coll. Cardiol. 2002. — Vol.39. — P.257−265.
- Hill J.M., Halox J.P.J. Circulating endothelial progenitor cells, vascular function and cardiovascular risk // New Engl. J. Med. 2003. — Vol.348. — P.593−600.
- John S., Schlaich M., Langenfeld M. et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study // Circulation. 1998. — Vol.98. — P.211−216.
- Schachinger V., Britten M.B., Eisner M. el al. A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation // Circulation. 1999. — Vol.100. P.1502−1508.
- Bergholm R., Leirisalo-Repo M., Vehkavaara S. et al. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis // Arteriol. Thromb. Vase. Biol. 2002. — Vol.22. — P. 1637−1641.
- Vaudo G., Marchesi S., Gerli R. et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity // Ann. Rheum. Dis. -2004. -Vol.63. -P.31−35.
- Hansel S., basing G., Pistrosch F. Et al. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity // Atherosclerosis. -2003. Vol.17. -P.177−180.
- Gonzalez-Juanatey C., Testa A., Garcia-Castelo A. et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis // Am. J. Med. -2003. Vol.114. -P.647−652.
- Hurlimann D., Forster A., Noll G. et al. Antitumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis // Circulation. 2002. — Vol.106. -P.2184−2187.
- Brand F.N., McGee D.L., Kannel W.B. et al. Hyperuricemia as a risk factor of coronary heart disease: The Framingham study // Am. J. Epidemiol. 1985. -Vol.121.-P.ll-18.
- Levine W., Dyer A.R., Shekelle R.B. et al. Serum uric acid and 11,5-year mortality of middle-aged women: findings of Chicago Heart Association Detection Project in Industry // J. Clin. Epidemiol. 1989. — Vol.42. — P.257−267.
- Yano K., Reed D.M., McGee D.L. Ten-year incidence of coronary heart disease in the Honolulu Heart Program. Relationship to biologic and lifestyle characteristics //Am. J. Epidemiol. 1984. — Vol.119. -P.653−666.
- Reunanen A., Takkunen H., Knekt P., Aromaa A. Hyperuricemia and risk of the cardiovascular mortality//Acta Med.Scand. 1982. — Vol.668. — P.49−59.
- Mortality findings for stepped-care participants in the Hypertension Detection and Follow-up Program, stratified by other risk factors. The Hypertension and Follow-up Program Cooperative Research Group // Prev. Med. 1985. — Vol.14. -P.312−335.
- Lehto S., Niskanen L., Ronnemaa Т., Laakso M. Serum uric acid is strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus // Stroke. 1998. — Vol.29. -P.635−639.
- Wannamethee S.G., Shaper A.G., Whincup P. H. Serum urate and the the risk of major coronary heart disease events // Heart. 1997. — Vol.78. — P.147−153.
- Selby J.V., Friedman G.D., Quesenberry C.P. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries // Am J. Epidemiol. 1990. — Vol.131 — P.1017−1027.
- Jossa F., Farinaro E., Panico S. et al. Serum uric acid and hypertension: the Olivetti heart study // J. Hum. Hypertens. 1994. — Vol.8. — P.677−681.
- Culleton B.F., Larson M.G., Kannel. W.B. et al. Semm uric acid and risk for cardiovascular disease and death: The Framingham Heart Study // Ann. Intern. Med. -1999.-Vol.131.-P.7.
- Wannamethee S.G., Shaper A.G., Whincup P.H. Serum urate and the risk of major coronary heart disease events // Heart. 1997. — Vol.78. — P. 147.
- Wheeler J.G., Juzwishin K.D., Eiriksdottir G. et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis // Proc. Natl. Acad. Sci. Med. 2005. — Vol. 2. — P.76.
- Johnson R.J., Kang D-H., Feig D. et al. Is there a pathogenic role for uric acid in hypertension and cardiovascular and renal disease? // Hypertension. 2003. -Vol.41. -P.1183−1190.
- Ames B.N., Cathcart R., Schwiers E. et al. Uric acid provides an antioxidant defense in human against oxidant- and radical-causing aging and cancer: a hypothesis // Proc. Natl. Acad. Sci. USA. 1981. — Vol.78. — P.6853−6862.
- Nieto F.J., Iribaren С., Gross N.D. et al. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? // Atherosclerosis. 2000. — Vol.148. -P.131−139.
- Bickel C., Rupprecht H.J., Blankenberg S. et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease // Am. J. Cardiol. 2002. — Vol.1. — Suppl.89 (1). — P.12−17.
- Hare J.H., Johnson R.J. Uric acid predicts clinical outcomes in heart failure // Circulation. 2003. — Vol.107. — P.1951−1953.
- Leyva F., Anker S.D., Godsland I.F. et al. Uric acid in chronic heart failure: a marker of chronic inflammation // Eur. Heart. J. 1998. — Vol.19. — P.1814 — 1822.
- Farquharson C.A., Butler R., Hill A. et al. Allopurinol improves endothelial dysfunction in chronic heart failure // Circulation. 2002. — Vol.106. — P.221 — 226.
- Doehner W., Schoene N., Rauchhaus M. et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure // Circulation. 2002. — Vol.105. -P.2619 -2624.
- Butler R., Morris A.D., Belch J.J.F. et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension // Hypertension. 2000 -Vol.35. -P.746−751.
- Mustard J.F., Murphy E.A., Ogryzlo M.A., Smythe H.A. Blood coagulation and platelet economy in subjects with primary gout // Can. Med. Assoc. J. 1963. -Vol.89.-P.1207−1211.
- Johnson W.D., Kayser K.L., Brenowitz J.B., Saedi S.F. A randomized controlled trial of allopurinol in coronary bypass surgery // Am. Heart J. 1991. -Vol.121. — P.20−24.
- Tabayashi K., Suzuki Y., Nagamine S. et al. A clinical trial of allopurinol (Zyloric) for myocardial protection // J. Thorac. Cardiovasc. Surg. 1991. — Vol.101. -P.713−718.
- Cappola T.P., Kass D.A., Nelson G.S. et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy // Circulation. 2001. -Vol.104. -P.2407−2411.
- Rao G.N., Corson M.A., Berk B.C. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression // J. Biol. Chem. 1991. — Vol.266. — P.8604−8608.
- Kang D.H., Nakagawa Т., Feng L. et al. A role for uric acid in the progression of renal disease // J. Am. Soc. Nephrol. 2002. — Vol.13. — P.2888−2897.
- Watanabe S., Kang D.H., Feng L. et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity // Hypertension. 2002. — Vol.40. — P.355−360.
- Kanelis J., Watanabe S., Li H.H. et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activaed protein kinase and cyclooxygenase-1 // Hypertension. 2003. — Vol.41. -P.1287−1293.
- Mazzali M., Hughes J., Kim Y.G. et al Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism // Hypertension. -2001.-Vol.38.-P.l 101−1106.
- Nakagawa Т., Mazzali M., Kang D-H. Hyperuricemia Causes Glomerular Hyprtrophy in the Rat // Am. J. Nephrol. 2002.
- O’Reilly S., Doherty M. Missed opportunity following diagnosis of gout // Ann. Rheum. Dis. 1995. — Vol.54. — P.86−87.
- Snaith M.L. ABC of rheumatology: gout, hyperuricaemia and crystal arthritis // Br. Med. J. 1995. — Vol.310. -P.521−524.
- Abbott R.D., Brand F.N., Kannel W.B. Gout and coronary heart disease: the Framingham Study // J. Clin. Epidemiol. 1988. — Vol.41. — P.237−242.
- Yu Т., Talbott J.H. Changing trends of mortality in gout // Semin. Arthirtis Rheum. 1980. — Vol.10. — P. l-9.
- Darlington L.G., Slack J., Scott J.T. Vascular mortality in patients with gout and in their families // Ann. Rheum. Dis.- 1983. Vol.42. — P. 270−273.
- Gelber A.C., Klag M.J., Mead L.A. et al. Gout and risk for subsequent coronary heart disease. The Meharry-Hopkins Study // Arch. Intern. Med. 1997. -Vol.157. -P.1436−1440.
- Janssens HJEM, van de Lisdonk E.H., Bor H. et al. Gout, just a nacsty event or cardiovascular signal? A study from primary care // Family Practice. 2003. — Vol.20. — P.423−416.
- Cristlieb A.R., Krolewski A.S., Warram J.H., Soeldner I.S. Is insulin the link between hypertention and obesity? // Hypertention. 1985. — Vol.7. — Suppl.II. -P.II54-II57.
- Manicardi V., Camellini L., Bellodi G., Ferrannini E. Evidence for an association of high blood pressure and hyperinsulinrmia in obese man // J. Clin. Endocrinol. Metab. 1986. — Vol.62. -P.1302 -1304.
- Rose H.G., Yalow R.S., Schweitzer P., Schwartz E. Insulin as a potential factor influencing blood pressure in amputees // Hypertension. 1986.- Vol.8. — P.793−800.
- Modan M., Halkin H., Almog S. et al. Hyperinsulinemia: a link between hypertention obesity and glucose intolerance // J. Clin. Invest. 1985. — Vol.75. -P.809 — 817.
- Tappy L., Bovet P., Jequier T. et al. Relationship ofof fasting serum insulin concentrations with blood pressure in a representative sample of the adult population of the Seychelles // Int. J. Obesity. 1991. — Vol.15. -P.669 — 675.
- Fournier A.M., Gadia M.T., Kubrusly D.B. et al. Blood pressure, insulin, and glycemia in nondiabetic subjects // Am. J. Med. 1986. — Vol.80. — P.861−864.
- Kuzell W.C., Schaffarzick R.W., Naugler W.E. et al. Some observations on 520 gouty patients // J.Chronic. Dis. 1995. — Vol.2. — P.645−669.
- Barlow K.A., Beilin L.J. Renal disease in primaiy gout // Q.J.Med., 1968. -Vol.37. -P.79−96.
- Rapado A. Relationship between gout and arterial hypertension // Adv. Exp. Med. Biol. 1974. — Vol.41. -P.451−459.
- Weiss Т.Е., Segaloff A. Gouty Arthritis and Gout // Springfield, III, Thomas. -1959.-P.7.
- Raison J., Safar M., Asmar R.E. et al. Sex dependent of body fat distribution and fluid volumes in hypertension // Kidney Int. 1988 — Vol.25. — P.122−124.
- Ford E.S., Cooper R.S. Risk factors for hypertension a national cohort study // Hypertension. 1991. — V.18 — № 5 — P. 598−606.
- Watson R.L., Langlord H.G. Weight, urinary electrolytes and blood pressure. Results of several community based studies // J.Chron.Dis. 1982. — Vol.35. -Suppl.12.- P.909−918.
- Rodnan G.P. A gallery of gout // Arthritis. Rheum. 1968. — Vol.4. — P.520−528.
- Khaodhiar L., McCowen K.C., Blackburn G.L. Obesity and comorbid conditions // Clin. Cornestone. 1999. — Vol. 2. — Suppl.3. — P. 17−31.
- Emmerson B. Hyperlipidemia, in hyperuricaemia and gout // Ann. Rheum. Dis. 1998. — Vol. 57.- P.509−510.
- Feldman E.B., Wallace S.L. Hypertriglyceridemia in gout //Circulation. -1964. -Vol.29. -P.508−513.
- Berkowitz D. Gout, hyperlipidemia and diabetes interrelationships // JAMA. -1966. Vol.197.-P.77−80.
- Benedek T.G. Correlations of serum uric acid and lipid concentrations in normal, gouty, and atherosclerotic men // Ann. Intern. Med. 1967. — Vol.66. -P.851−861.
- Barlow K.A. Hyperlipidemia in primary gout // Metabolism. 1968. — Vol.17. -P.289−299.
- Jiao S., Kameda K., Matsuzava Y. et al. Hyperlipoproteinaemia in primary gout: Hyperlipoproteinaemic phenotype and influence of alcohol intake and obesity in Japan // Ann.Rheum. Dis. 1986. — Vol.45. -P.308−313.
- Takahashi S., Yamamoto Т., Moriwaki Y. et al. Impaired lipoprotein metabolism in patients with primary gout Influence of alcohol intake and body weight // Br. J. Rheumatol. — 1994. — Vol. 33. — P.731−734.
- Takahashi S., Yamamoto Т., Moriwaki Y. et al. Increased concentrations of serum Lp (a) lipoprotein patients with primary gout // Ann. Rheum. Dis. 1995. -Vol.54. -P.90−93.
- Genest J.J., Jenner J.L., McNamara J.R. et al. Prevalence of lipoprotein (a) excess in coronary artery disease // Am. J. Cardiol.-1991. Vol.67 — P. 1039−1045.
- Choi H.K., Atkinson K., Karlson E.W. et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men // New. Engl. J. Med. 2004. — Vol.350. -P.1093−1103.
- Faccini F., Ida Chen Y.D., Hollenbeck C.B. et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance and plasma uric acid concentration // JAMA.- 1999. Vol.266. -P.3008−3011.
- Kahn A.M. Indirect coupling between sodium and urate transport in the proximal tubule // Kidney Int. 1989. — Vol.36. — P.378.
- Takahashi S., Moriwaki Y., Tsutsumi Z. et al. Increased visceral fat accomulation further aggravates the risk of insulin resistance in gout // Metabolism. -2001. Vol.50. — Suppl.4. — P.393- 398.
- Mikkelsen W.M. The possible association of hyperuricemia and/or gout with diabetes mellitus // Arthritis Rheum. 1965. — Vol.8. — P.853−864.
- Berkowitz D. Gout, hyperlipidemia and diabetes interrelationships // JAMA. -1966.-Vol.197.-P.77−80.
- Myers A., Epstein F.H., Dodge H.J. The relationship of serum uric acid to risk factors in coronary heart disease // Am. J. Med. 1968. — Vol.45. — P.520−528.
- Herman J.B., Mount F.W., Medalie J.H. et al. Diabetes prevalence and serum uric acid: Observations among 10,000 men in a survey of ischemic heart disease in Israel // Diabetes. 1967. — Vol.16. — P.858−868.
- Padova J., Patchefsky A., Onesti G. et al. The effect of glucose loads on renal uric acid excretion in diabetic patients // Metabolism. 1964. — Vol.13. — P.507−512.
- Bo S., Cavallo-Perin P., Gentile L. et al. Hypouricaemia and hyperuricaemia in type 2 diabetes: two different phenotypes // Eur. J. Clin. Invest. 2001. — Vol.31. -Suppl.4. -P.318−321.
- Goodson NJ., Symmons D.B.M., Scott D.G.I., et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis// Arthritis Rheum. 2005. — Vol.52(8). — P.2293−2299.
- Schumacher HR.Jr. Crystal-induced arthritis: an overview // Am. J. Med. -1996. Vol.100. — 46S-52S.
- Terkeltaub R.A. Pathogenesis and treatment of crystal-induced inflammation. In: Koopman W.J. editor // Arthritis and allied conditions. Philadelphia. -Lippincott Williams & Wilkins. — 2001. — P. 2329−2347.
- Ginsberg M.H., Kozin F., Chow D. et al. Adsorption of polymorphonuclear leukocyte lysosomal enzymes to monosodium urate crystals // Arthritis Rheum. -1977. Vol.20. — P. 1538−1542.
- Guerne P.A., Terkeltaub R., Zuraw B. et al. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes // Arthritis Rheum. 1989. — Vol.32. -P.1443−1452.
- Pouliot M., James M.J., McColl S.R. et al. Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes // Blood. 1998. — Vol.91. — P.1769−1776.
- Bouchard L., de Medicis R., Lussier A. et al. Inflammatory microcrystals alter the functional phenotype of human osteoblast-like cells in vitro: synergism with IL-1 to overexpress cyclooxygenase-2 // J. Immunol. 2002. — Vol.168. -P.5310−5317.
- Di Giovine F.S., Malawista S.E., Nuki G. et al. Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced LL 1 // J. Immunol. 1987. — Vol.138. — P.3213−3218.
- Насонов E.JI. Проблема атеротромбоза в ревматологии // Вестник РАМН. -2003. -№ 7.-С.6−10.
- Di Giovine F.S., Malawista S.E., Thornton E. et al. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells // J. Clin. Invest. 1991. — Vol.87. — P. 1375−1381.
- Seegmiller J.E., Howell R.R., Malawista S.E. The inflammatory reaction to sodium urate // JAMA. 1962. — Vol.180. — P.469−475.
- McCarty DJ. Jr. The inflammatory reaction to microcrystalline sodium urate // Arthritis Rheum. 1965. — Vol.8. -P.726−735.
- Sesso H.D., Buring J.E., Rifai N. et al. C-reactive protein and the risk of developing hypertension // JAMA. 2003. — Vol.290. — P.2945−2951.
- Pradhan A.D., CookN.R., Buring J.E. et al. C-reactive protein is independently associated with fasting insulin in nondiabetic women // Arterioscler. Thromb. Vase. Biol. 2003. — Vol.23. -P.650−655.
- Pradhan A.D., Manson J.E., Rifai N. et al. C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus // JAMA. 2001. — Vol.286. — P.327−334.
- Freeman D.J., Norrie J., Caslake M.J. et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study // Diabetes. 2002. — Vol.51. — P. 1596−1600.
- Barzilay J.I., Abraham L., Heckbert S.R. et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study // Diabetes. 2001. — Vol.50. — P.2384−2389.
- Thorand В., Lowel H., Sclmeider A. et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984 -1998 // Arch. Intern. Med. 2003. — Vol.163. — P.93−99.
- Hu F.B., Meigs J.B., Li T.Y. et al. Inflammatory markers and risk of developing type 2 diabetes in women // Diabetes. 2004. — Vol.53. — P.693−700.
- Schulze M.B., Rimm E.B., Li T. et al. C-reactive protein and incident cardiovascular events among men with diabetes // Diabetes Care. 2004. — Vol. 27. -P.889−894.
- Ridker P.M., Buring J.E., Cook N.R. et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women // Circulation. 2003. — Vol.107. — P.391−397.
- De Groot E., Hovingh K., Wiegman A. et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis // Circulation. 2004. — Vol.109 (suppl III). — P.33−38.
- Del Rincon I., Williams K., Stern M.P. et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects // Arthritis Rheum. 2003. — Vol.48. — P.1833−1840.
- Kumeda Y., Inaba M., Goto H. et al. Increased thickness of the arterial intima-medis detected by ultrasonography in patients with rheumatoid arthritis // Arthritis Rheum. 2002. — Vol.46. — P.1489−1497.
- Nagata-Sakurai M., Inaba M., Goto H. et al. Inflammation and bone resorbtion as independent factors of accelerated arterial wall thicening in patients with rheumatoid arthritis //Arthritis Rheum. 2003. — Vol.48. — P.3061−3067.
- Alkaabi J.K., Ho M., Levinson R. et al. Rheumatoid arthritis and macrovascular disease // J.Rheumatol. 2003. — Vol.42. — P.292−297.
- Wallace S.L., Robinson H.3 Masi A. et al. Preliminary criteria for the classification of the acute arthritis of primary gout // Arthritis Rheum. 1977. -Vol.20. -P.895−900.
- Артериальная гипертония (Рекомендации ВОЗ и МОАГ). Москва. -1999.-С.18.
- АСС/АНА Task Force Heart Failure guidelines. Guidelines for Evalution and Management of Heart Failure Report of the American College of Cardiology/ American Heart assotiation Task Force on Practice Guidelines // JACC. 1995. -Vol. 26.(5).-P.1376−1398.
- Hulley S., Grady D., Bush T. et al. Randomized trial of Estrogen Plus World Health Organization: Report of a WHO Consultation: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications // Geneva, 1999.
- Перова H.B. суммарный риск ИБС и показания к лечению гиперхолестеринемии (применение Европейских рекомендаций к российским условиям) // Кардиология. 1996. — С. 49−53.
- Рекомендации по профилактике, диагностике и лечению Артериальной Гипертонии // Всероссийское научное общество кардиологов, 2002.
- Celermajer D. S, Sorensen K.E., Gooch V.M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk atherosclerosis // Lancet. -1992.-Vol. 340.-P.l 111−1115.
- Vague J. La differentiation sexuelle, facteur d terminant des formes de 1'obesiL // Presse Med. 1947. — Vol.30 — P. 339−340.
- Бутрова C.A. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению // РМЖ. 2001. — № 2(9). — С.56−60.
- Мельниченко Г. А. Ожирение в практике эндокринолога // РМЖ. 2001. -№ 2 (9). — С.82- 87.
- Насонов E.JI. Маркеры воспаления и атеросклероз: значение С-реактивного белка// Кардиология. 1999. — № 2. — С.81−85.
- Насонов ЕЛ. Иммунологические маркеры атеросклероза // Тер. Архив. -2002. № 5. — С.80−85.
- Насонов E. JL, Панюкова Е. В., Александрова Е. Н. С-реактивный белок -маркер воспаления при атеросклерозе (новые данные) // Кардиология. 2002. -№ 7. — С. 53−60.
- Albert М.А., Glynn R.J., Ridker P.M. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score // Circulation. 2003. — Vol. 108. — P.161−165.
- Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention // Circulation. 2003. — Vol.107. — P.363−369.
- Ridker P.M., Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Score // Circulation. -2004. Vol.109.-P. 1955−1959.
- Pasceri V., Yeh E.T. A tale of two diseases: atherosclerosis and rheumatoid arthritis// Circulation. 1999. — Vol.100. -P.2124−2126.
- Gonzalez-Gay M.A., Gonzalez-Juanatey C., Pineiro A. et al. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis // J. Rheumatol. 2005. — Vol.32. — P.1219−1223.
- Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction. A marker of atherosclerotic risk // Arteriol. Thromb. Vase. Biol. 2003. — Vol. 23. — P. 168−175.
- Wildansky M.E., Gokce N., Keaney J.F. et al. The clinical implications of endothelial dysfunction. J. Amer. Coll. Cardiol. 2003. — Vol.42. -P.l 149−1160.
- Gokee N., Keaney GFG., Hunter L.M. et al. Risk stratification for prospective cardiovascular events via noninvasive assessment of endothelial function: a prospective study // Circulation. 2002. — Vol.105. — P. 1567−1572.
- Vita JA., Keaney JF. Jr. Endothelial function: a barometer for cardiovascular risk? // Circulation. 2002. — Vol.106. — P.640−642.
- Gokee N., Keaney GFG., Hunter L.M. et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease // J. Am. Coll. Cardiol. 2003. — Vol. 41. — P.1769−1775.
- Tatura M.-C., Heinrich J., Junker R. et al. C-reactive protein and tl» severity of atherosclerosis in myocardial infarction patients. w' stable angina pectoris // Eur. Heart J. 2000. — Vol.21. — P. 1000−1008.
- Ridker P.M., Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Score // Circulation. -2004. Vol.109. -P.1955−1959.
- Pasceri V., Yeh E.T. A tale of two diseases: atherosclerosis and rheumatoid arthritis// Circulation. 1999. — Vol.100. -P.2124−2126.
- Gonzalez-Gay M.A., Gonzalez-Juanatey C., Pineiro A. et al. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis // J. Rheumatol. 2005. — Vol.32. — P. 1219−1223.
- Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction. A marker of atherosclerotic risk//Arteriol. Thromb. Vase. Biol. -2003. Vol. 23. -P.168−175.
- Wildansky M.E., Gokce N., Keaney J.F. et al. The clinical implications of endothelial dysfunction. J. Amer. Coll. Cardiol. 2003. — Vol.42. — P. 1149−1160.
- Gokee N., Keaney GFG., Hunter L.M. et al. Risk stratification for prospective cardiovascular events via noninvasive assessment of endothelial function: a prospective study//Circulation. 2002. — Vol.105. — P. 1567−1572.
- Vita JA., Keaney JF. Jr. Endothelial function: a barometer for cardiovascular risk? // Circulation. 2002. — Vol.106. — P.640−642.
- Tatura M.-C., Heinrich J., Junker R. et al. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris // Eur. Heart J. 2000. — Vol.21. — P.1000−1008.
- Gatcia-Moll X., Zouridakis E., Cole D. et al. C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men // Eur. Heart J. 2000. — Vol.21. — P. 1598−1606.